Yunrui Intelligence Completes Tens of Millions of Yuan Strategic Financing to Accelerate In- and Out-of-Hospital Healthy Sleep Ecosystem Development

Recently, Shenzhen Chuangda Yunrui Intelligent Technology Co., Ltd. (“Yunrui Intelligence”), a provider of bio-information sensing and artificial intelligence solutions centered on brain-computer interface technology, announced the completion of a strategic financing round amounting to tens of millions of yuan. This round was exclusively invested by Shengyu Investment, and the proceeds will be used to further accelerate the company’s layout and development in China’s smart sleep monitoring market.

Yunrui Intelligence’s flagship product, the UMindSleep forehead-mounted sleep recorder, has obtained medical device registration certification from the National Medical Products Administration (NMPA). It can be directly deployed in clinical departments of healthcare institutions, where its sleep staging data parameters and analytical results serve as reference evidence for disease analysis in patients with sleep disorders, thereby greatly facilitating physicians’ diagnostic workflows.

Youmengsi EEG Sleep Monitoring Solution

In the field of multi-modal biometric data acquisition and analysis centered on electroencephalography (EEG), Yunrui Intelligence has independently developed system equipment and core AI algorithmic analysis technologies, for which it has filed dozens of globally leading patents and secured over one hundred intellectual property rights.

It is understood that the UMindSleep forehead-mounted wireless EEG sleep monitoring device can accurately capture high-precision physiological parameters, including electroencephalogram (EEG), blood oxygen saturation, pulse rate, body position, and body movement. By automatically completing data acquisition, upload, analysis, and feedback, the device provides real-time, continuous sleep stage monitoring services for individuals in a sub-health state and patients with sleep disorders, thereby significantly addressing the challenges of poor adoption and low efficiency in the promotion of sleep health solutions within China.

According to statistics from the National Health and Family Planning Commission, by the end of 2020, the total number of medical institutions in China was approximately 1.02 million, including 2,996 tertiary hospitals, 10,404 secondary hospitals, 12,252 primary hospitals, and over 970,000 other grassroots medical institutions. Experts estimate that the existing market size for EEG sleep monitoring equipment is around RMB 21.8 billion. Clinically, polysomnography (PSG) serves as the gold standard for diagnosing various sleep disorders and identifying the causes of insomnia within hospitals. Although highly accurate, its complex operation limits its application scenarios and, to some extent, reduces the efficiency of sleep monitoring in medical facilities. Therefore, more convenient wearable and intelligent monitoring devices will significantly increase the adoption rate of in-hospital sleep monitoring and create greater development opportunities. Conservatively, the incremental market is estimated to reach as high as RMB 44.5 billion.

In the medical market, the U-Mind EEG sleep monitoring solution enables in-hospital networked sleep monitoring and manages sleep surveillance across multiple wards and departments. Leveraging an integrated information technology host device, it supports simultaneous sleep monitoring for hundreds of patients within a hospital. Its overall sleep staging accuracy exceeds 97.67% of the average level achieved by expert manual scoring, providing physicians with comprehensive AI-driven sleep analysis reports and clinical decision support recommendations.

Currently, U-Mind has established collaborations with hundreds of medical institutions, research institutes, sleep centers, health examination centers, wellness and care facilities, and third-party health management organizations both in China and abroad, all achieving results that exceed expectations.

As public health awareness continues to rise, sleep quality has become a buzzword in recent years, with young people paying increasing attention to their sleep. It is reported that approximately 450 million people in China suffer from varying degrees of sleep problems each year, yet fewer than 2% seek medical consultation at hospitals. The rate of accurate diagnosis remains extremely low, and the vast majority of individuals are still in the stage of blindly selecting solutions.

To capitalize on the vast opportunities in the home-use market, the U-Mind EEG sleep monitoring solution leverages a compact smart device paired with a dedicated app to generate comprehensive sleep health assessment reports. These reports provide precise records of key parameters, including sleep stages, blood oxygen saturation, pulse rate, snoring, body position, and body movements. This enables users to gain better insights into their sleep patterns, cultivate healthy lifestyle habits, and facilitates early warning and screening for sleep disorders.

In building a closed-loop ecosystem for the diagnosis and treatment of sleep disorders, Yunrui Intelligence leverages its core EEG technology and partners with Yuwell Medical, a leading medical device R&D and manufacturer, to jointly create an integrated “diagnosis and treatment” solution for sleep disorders caused by respiratory, endocrine, and other diseases.

Yuwell Medical’s non-invasive ventilators, blood pressure monitors, and blood glucose meters have achieved significant market share both within and outside hospitals. Through this strategic partnership, the two parties can leverage their respective product and channel advantages to address the challenges of promoting widespread adoption and improving efficiency in precise diagnosis across numerous medical institutions and households, thereby helping patients with sleep disorders rapidly enhance their treatment outcomes.

Yunrui Intelligence Exhibited at the Yuwell Booth of the 84th CMEF International Medical Device Exhibition

Since 2011, Shengyu Medical’s investment team has focused its strategic layout in the broader healthcare industry on three core sectors: in vitro diagnostics (IVD) and biopharmaceuticals, medical devices and consumables, and smart healthcare, guided by the strategies of “specialization” and “industry partnership.” In the smart healthcare sector, Shengyu has invested in a number of technological leaders in niche markets, fostering product and channel synergies within the Shengyu Medical ecosystem.

A China A-share listed company established in 1998. As one of the largest medical device suppliers in China, it serves over 300,000 healthcare institutions domestically and more than 90% of Grade III Class A hospitals, with a presence in over 110 countries and regions overseas, benefiting 300 million households worldwide. Building on its cornerstone businesses in blood pressure monitoring, temperature monitoring, traditional Chinese medicine equipment, and surgical instruments, the company’s product strategy focuses on three core sectors: respiratory care, diabetes management, and infection control, while incubating three emerging sectors: emergency care, ophthalmology, and intelligent rehabilitation.